Trial Details 102 Total Sites

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)

phase

Phase 3

status

Recruiting

enrollment

2300

score

61

start date

2018-08-02

last updated

2022-01-13

New York City, New York
facility
Memorial Sloan Kettering Cancer Center
1 facility
Recruiting
Los Angeles, California
facility
Cedars-Sinai Medical Center
1 facility
Recruiting
Jacksonville, Florida
facility
Baptist - MD Anderson Cancer Center
1 facility
Recruiting
Baltimore, Maryland
facility
Mercy Medical Center
facility
University of Maryland Greenebaum Comprehensive Cancer Center
2 facilities
Recruiting
Nashville, Tennessee
facility
SCRI
1 facility
Recruiting
Wichita, Kansas
facility
Cancer Center of Kansas
1 facility
Recruiting
Des Moines, Iowa
facility
Des Moines Oncology Research Association
1 facility
Recruiting
Rochester, New York
facility
Rochester General Hospital; Lipson Cancer and Blood Center
1 facility
Recruiting
Concord, California
facility
John Muir Health Clinical Research Center
1 facility
Recruiting
Manchester, New Hampshire
facility
New Hampshire Hematology Oncology
1 facility
Recruiting
Huntington, West Virginia
facility
St. Mary's Medical Center
1 facility
Recruiting
Lake Success, New York
facility
Monter Cancer Center
1 facility
Recruiting